TY - JOUR
T1 - Use of tumour-responsive T cells as cancer treatment
AU - Disis, Mary L.
AU - Bernhard, Helga
AU - Jaffee, Elizabeth M.
N1 - Funding Information:
MLD is supported by US National Institutes of Health (NIH) grants CA85374 and CA101190, and Athena Water. HB is supported by grants from the Research Council of Germany SFB 456, the Wilhelm Sander Foundation and the GSF National Research Center for Environment and Health-Clinical Cooperation Group Vaccinology. EMJ is supported by the Dana and Albert “Cubby” Broccoli Professorship; NIH grants U19CA72108, P50CA88843, and CA62924; and the Sol Goldman Pancreatic Cancer Research Center. We thank Sally Zebrick, Molly Boettcher, and Julia Muller for assistance in manuscript preparation.
PY - 2009
Y1 - 2009
N2 - The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.
AB - The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.
UR - http://www.scopus.com/inward/record.url?scp=60249091474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60249091474&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(09)60404-9
DO - 10.1016/S0140-6736(09)60404-9
M3 - Review article
C2 - 19231634
AN - SCOPUS:60249091474
SN - 0140-6736
VL - 373
SP - 673
EP - 683
JO - The Lancet
JF - The Lancet
IS - 9664
ER -